tiprankstipranks
Coya Therapeutics initiated with a Buy at D. Boral Capital
The Fly

Coya Therapeutics initiated with a Buy at D. Boral Capital

D. Boral Capital initiated coverage of Coya Therapeutics (COYA) with a Buy rating and $15 price target Coya believes that through exactly the right combination, concentration, and dose of IL-1 and CTLA4, the company can ameliorate the deleterious out of a balanced immune system that contributes to the rapid decline seen in amyotrophic lateral sclerosis patients, the analyst tells investors in a research note. The firm says a small proof-of-concept study demonstrated the viability of the approach. Coya developed a pioneering approach to treat neurodegenerative disorders by addressing inflammation in the brain, it adds.

Pick the best stocks and maximize your portfolio:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App